08/11/2026
President Trump has helped unleash an extraordinary new wave of investment in American medicine, with pharmaceutical companies announcing roughly $500 billion in new U.S. investments in research, manufacturing, and infrastructure.
Now, a Biden-era drug pricing system threatens to undermine that progress.
When scientists develop treatments that can turn hours in an infusion chair into minutes, reduce the burden on patients, and allow care to be delivered in less expensive settings, that is innovation. Federal bureaucrats should not be able to change the rules after years of research and investment and decide otherwise.
We can lower costs for American patients while protecting the innovation that produces tomorrowโs treatments and cures.
Read my latest:
CMS should withdraw this provision that would prematurely combine separately developed and separately approved medicines for purposes of government price setting.